

THC BIOMED INTL LTD.
P.O. Box 20033 Towne Centre
Kelowna, B.C. V1Y 9H2
www.thcbiomed.com

THC BioMed (Thailand) Launches State-of-the-Art Medical Cannabis THC2GO Dispensary

THC.CSE THCBF - OTC TFHD.F

Vancouver, Canada – June 20, 2023 - THC BioMed Intl Ltd. ("**THC BioMed**" or the "**Company**"), a prominent Canadian licensed producer, proudly announces the highly anticipated official opening of a THC2GO medical cannabis dispensary in Thailand by THC BioMed (Thailand) Co. Ltd. ("**THC Thailand**"). This strategic move represents a significant milestone for THC BioMed as it positions itself as a global player, tapping into the flourishing Southeast Asian market.

Because of applicable foreign ownership rules, THC Thailand is 51% owned by a Thai-owned company. THC BioMed owns 49%, with 9% of that being held in trust by THC BioMed for an arm's length party. Located in the vibrant city of Rawai, Phuket, the cutting-edge THC2GO medical cannabis dispensary signifies THC BioMed's unwavering commitment to delivering superior healthcare solutions and elevating the standards of medical cannabis treatment across international borders.

THC Thailand's THC2GO dispensary offers an extensive selection of top-tier medical cannabis products meticulously crafted to meet the most stringent quality criteria. Our unrivaled cultivation practices and unwavering compliance with strict regulatory protocols ensure that patients receive safe, reliable, and consistently exceptional cannabis offerings.

In addition to providing patients with an extensive range of high-quality medical cannabis products, THC BioMed is proud to forge strong alliances with local businesses, healthcare professionals, researchers, and regulatory bodies. Collaborating with esteemed medical practitioners, we aim to foster a culture of education, evidence-based practices, and knowledge sharing about the remarkable potential of medical cannabis.

"We are thrilled with the opening of our state-of-the-art THC2GO medical cannabis dispensary in Thailand," said John Miller, CEO of THC BioMed. "This expansion underscores our unwavering commitment to making a positive impact on global healthcare. We are dedicated to serving patients, fostering research initiatives, and driving the medical cannabis movement forward in Thailand."

For more information, media inquiries, or exciting partnership opportunities, please contact

THC BioMed Intl Ltd. at marketing@thcbiomed.com or the following:

President and CEO:

John Miller THC BioMed Intl Ltd.

T: 1-844-THCMEDS
E: info@thcbiomed.com

About THC

THC BioMed is one of Canada's oldest active licensed cannabis companies. It was first licensed to deal with cannabis in 2013 under a Health Canada Section 56 exemption under the *Controlled Drugs and Substances Act* and has been a Licensed Producer under the current regime since 2016. Its product focus is on high-quality, high-potency beverages and edibles.

THC BioMed is a *Cannabis Act* Licensed Producer of medical and recreational cannabis. It is licensed to cultivate and sell dried, extract, edible and topical cannabis. The Company is on the leading edge of scientific research and the development of products and services in the medical and recreational cannabis industry. Management believes THC BioMed is well-positioned to be in the forefront of this industry.

Forward-Looking Information:

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of THC BioMed. Forward-looking information is based on certain key expectations and assumptions made by the management of THC BioMed. In some cases, you can identify forward-looking statements using words such as "will," "may," "would," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue," "likely," "could" and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Forward-looking statements in this release include that (a) THC2Go will cause THC BioMed to position itself as a global player and tap into the Southeast Asian market, (b) the Southeast Asian medical cannabis market will flourish, (c) THC BioMed will elevate the standards of medical cannabis treatment across international borders and (d) the products sold by the dispensary will be top-tier medical cannabis that is high-quality, safe, reliable, and consistently exceptional and (e) the Company is well-positioned to be in the forefront of this industry. Forward-looking statements in this release are made as of the date of this press release and include that THC BioMed will be on the forefront of this rapidly growing industry. Although THC BioMed believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because THC BioMed can give no assurance that they will prove to be correct. THC disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

The Canadian Securities Exchange (CSE) has not reviewed and does not accept responsibility for the adequacy or the accuracy of the contents of this release.